Share

December 14, 2021; 97 (24) Contemporary Issues in Practice, Education, & Research

Comment: Introducing Neurologic Therapeutics in 2035

Lyell K. Jones, Robert A. Gross
First published December 13, 2021, DOI: https://doi.org/10.1212/WNL.0000000000012977
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
50

Share

Article Information

vol. 97 no. 24 1120
DOI: 
https://doi.org/10.1212/WNL.0000000000012977
PubMed: 
34903612
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • First Published December 13, 2021.
Copyright & Usage: 
© 2021 American Academy of Neurology

Author Disclosures

    1. Lyell K. Jones Jr, MD and
    2. Robert A. Gross, MD, PhD
  1. Lyell K. Jones Jr, MD and
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Neurology: Clinical Practice, Editorial Board, 2016 to present

    Patents:

    1. NONE

    Publishing Royalties:

    1. Mayo Clinic Neurology Board Review book, Oxford University Press, 2015

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other activities:

    1. Voluntary member of the AANI Board of Directors Voluntary member of the Mayo Clinic ACO Board of Directors Voluntary chair of the American Academy of Neurology Quality Committee Teaching honoraria from the American Academy of Neurology

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Robert A. Gross, MD, PhD
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Received honorarium from AAN as Editor-in-Chief of Neurology (through Q1 2020).

    Editorial Boards:

    1. Served as Editor-in-Chief of Neurology 2009-2020.

    Patents:

    1. NONE

    Publishing Royalties:

    1. Neurology in Practice (series); Blackwell-Wiley; 2011-2021

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical procedures or imaging studies:

    1. Has conducted clinical trials funded by GlaxoSmithKline, UCB, Ortho-McNeil, Pfizer, and Marinus, but has ceased participation in industry-sponsored clinical trials and speakers' bureau since appointment as EIC for Neurology (2009).

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. 1) UL1 TR002001 Bennett/Zand (MPI) 07/15/2020 - 06/30/2025 NIH/National Center for Advancing Translational Sciences The University of Rochester’s Clinical and Translational Science Institute $19,107,872 2% effort on Digital Health & Regulatory Science; 5% effort on the Translational Endeavors Core (ended on 12/31/2020)

    Research Support, Academic Entities:

    1. UT Austin: Grand Rounds Honorarium ($500) - 2021 Stock/Stock Options, Medical Equipment & Materials: Note: All since term as editor ended 1. Amgen, 2020- 2. GSK, 2020- 3. J&J, 2020- 4. Merck, 2020- 5. Pfizer, 2020- 6. Procter & Gamble, 2020-

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Mayo Clinic (L.K.J.), Rochester, MN; and University of Rochester (R.A.G.), NY.

Article usage

Article usage: December 2021 to October 2023

AbstractFullPdfSource
Dec 20214464330Highwire
Jan 20228999Highwire
Feb 202210511Highwire
Mar 20225711Highwire
Apr 20224811Highwire
May 20226322Highwire
Jun 20223101Highwire
Jul 20224601Highwire
Aug 20225450Highwire
Sep 20225811Highwire
Oct 20227332Highwire
Nov 20226920Highwire
Dec 20226711Highwire
Jan 20234800Highwire
Feb 20233340Highwire
Mar 20234330Highwire
Apr 20232900Highwire
May 20232100Highwire
Jun 20232700Highwire
Jul 20233200Highwire
Aug 20234700Highwire
Sep 20232300Highwire
Oct 20232530Highwire

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. [email protected]
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Topics Discussed

Alert Me